The rise and fall of β-agonists in the treatment of ARDS
Open Access
- 1 January 2012
- journal article
- review article
- Published by Springer Nature in Critical Care
- Vol. 16 (2) , 208
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trialThe Lancet, 2012
- Randomized, Placebo-controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: A randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndromeTrials, 2011
- The Beta Agonist Lung Injury TrIal (BALTI) - prevention trial protocolTrials, 2011
- Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury*Critical Care Medicine, 2010
- Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogsCritical Care, 2009
- Alveolar Epithelial β 2 -Adrenergic ReceptorsAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Alveolar edema fluid clearance and acute lung injuryRespiratory Physiology & Neurobiology, 2007
- In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injuryThorax, 2007
- Association Between Inhaled β-Agonists and the Risk of Unstable Angina and Myocardial InfarctionChest, 2002